Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Despite the large differences in the epidemiology of hypertension across Europe, treatment strategies are similar for national populations of white European descent. However, hypertensive patients of African or South Asian ethnicity may require ethnic-specific approaches, as these population subgroups tend to have higher blood pressure at an earlier age that is more difficult to control, a higher occurrence of diabetes, and more target organ damage with earlier cardiovascular mortality. Therefore, we systematically reviewed the evidence on antihypertensive drug treatment in South Asian and African ethnicity patients. We used the Cochrane systematic review methodology to retrieve trials in electronic databases including CENTRAL, PubMed, and Embase from their inception through November 2015; and with handsearch. We retrieved 4596 reports that yielded 35 trials with 7 classes of antihypertensive drugs in 25,540 African ethnicity patients. Aside from the well-known blood pressure efficacy of calcium channel blockers and diuretics, with lesser effect of ACE inhibitors and beta-blockers, nebivolol was not more effective than placebo in reducing systolic blood pressure levels. Trials with morbidity and mortality outcomes indicated that lisinopril and losartan-based therapy were associated with a greater incidence of stroke and sudden death. Furthermore, 1581 reports yielded 16 randomized controlled trials with blood pressure outcomes in 1719 South Asian hypertensive patients. In contrast with the studies in African ethnicity patients, there were no significant differences in blood pressure lowering efficacy between drugs, and no trials available with mortality outcomes. In conclusion, in patients of African ethnicity, treatment initiated with ACE inhibitor or angiotensin II receptor blocker monotherapy was associated with adverse cardiovascular outcomes. We found no evidence of different efficacy of antihypertensive drugs in South Asians, but there is a need for trials with morbidity and mortality outcomes. Screening for cardiovascular risk at a younger age, treating hypertension at lower thresholds, and new delivery models to find, treat and follow hypertensives in the community may help reduce the excess cardiovascular mortality in these high-risk groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325 · cited 2×
“Also, we need data on whether lower thresholds to start treatment and lower therapeutic goal blood pressures need to be applied [111].”
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Hypertension in Sub-Saharan African Populations
Opie, L. H., & Seedat, Y. K. (2005) · Circulation · doi:10.1161/circulationaha.105.539569 · Cited by 456 · cited 3×
“In addition, hypertension occurs earlier in life in these patients groups, bringing about a faster progression from normotension to hypertension, with higher mean blood pressures than in white patients [3–22].”
Self-citationGraudal, N., Jürgens, G., Baslund, B., & Alderman, M. H. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu028 · Cited by 407 · cited 1×
“These measures are thought to be effective in hypertensives across ethnic groups, but increasing evidence indicates that the very low salt intake (\1500 mg or \65 mmol sodium per day) recommended for persons of African ethnicity [31–33], has been associated with increased mortality in this group, potentially related t…”
Reisin, E., Weir, M. R., Falkner, B., Hutchinson, H. G., Anzalone, D. A., & Hypertension, M. L. T. F. T. T. I. O. P. W. (1997) · Hypertension · doi:10.1161/01.hyp.30.1.140 · Cited by 158
Kalogeropoulos, A. P., Georgiopoulou, V. V., Murphy, R. A., Newman, A. B., Bauer, D. C., Harris, T. B., Yang, Z., Applegate, W. B., & Kritchevsky, S. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6278 · Cited by 116 · cited 2×
“Even so, high salt intake ([2300 mg or [100 mmol sodium per day) is still considered detrimental to cardiovascular health [32], and moderate salt restriction continues to have a place in the management of hypertension in all ethnic groups.”
Ethnic differences in associations between blood pressure and stroke in south Asian and European men
Eastwood, S. V., Tillin, T., Chaturvedi, N., & Hughes, A. D. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05672 · Cited by 82
The DASH diet enhances the blood pressure response to losartan in hypertensive patients
Conlin, P. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00056-6 · Cited by 76 · cited 2×
“ABC Association of Black Cardiologists, TAIM Trial of Antihypertensive Interventions and Management, TOMHS Treatment of Mild Hypertension Study, TROPHY Treatment in Obese Patients with Hypertension [36–66] c 360 Intern Emerg Med (2016) 11:355–374”
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
“• Management of hypertension: – South East Asia: Standard treatment as indicated in these guidelines is advised, until more evidence becomes available.(138) Section 11: Resources”
The impact of ethnicity on clinical outcomes in COVID-19: A systematic review
Pan, D., Sze, S., Minhas, J. S., Bangash, M. N., Pareek, N., Divall, P., Williams, C. M., Oggioni, M. R., Squire, I. B., Nellums, L. B., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100404 · Cited by 519
Rehan, H. S., Grover, A., & Hungin, A. P. S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0715-4 · Cited by 9
Metadata
- Authors
- Brewster, L. M., van Montfrans, G. A., Oehlers, G. P., & Seedat, Y. K.
- Venue
- Internal and Emergency Medicine
- Published
- 2016-03-30
- Volume
- 11
- Issue
- 3
- Pages
- 355-374
- ISSN
- 1828-0447 (ISSN-L)
- 1970-9366
- OpenAlex
- W2327764009
- Cited by
- 71
- References
- 10
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. https://app.cochat.ai/papers/10.1007/s11739-016-1422-x
- The paper
- Brewster, L. M., van Montfrans, G. A., Oehlers, G. P., & Seedat, Y. K. (2016). Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-016-1422-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.